UCL's gene therapy developer has followed a $120m round co-led by Novo three weeks ago by filing to go public on the Nasdaq Global Select Market.

Freeline, a UK-based gene therapy spinout from University College London (UCL) formed by commercialisation firm Syncona, has filed for a $100m initial public offering in the United States that will give pharmaceutical firm Novo the chance to exit. Freeline is developing adeno-associated virus (AAV) gene therapies, and the AAVS3 virus that forms the basis of…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.